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Human ABC (ATP Binding Cassette) proteins are ATP utilizing transmembrane 
transporters that pumps substrates across the plasmamembrane and intracellular 
membranes. The functional core unit of ABC transporters consists of two ABC domains 
and two transmembrane domains. The ABC domains are organised in head to tail 
orientation to form two composite catalytic sites that close upon ATP binding. The two 
nucleotide-binding pockets are formed by Walker-A and Walker-B motifs of one 
nucleotide binding fold (ABC domain) and by the signature motif of the opposite 
nucleotide-binding fold. Transmembrane domains that form the substrate translocation 
pore are connected to the catalytic ABCs through rigid helices that transmit conformational 
changes generalized during the ATP-cycle. 
Mutations within the ABCC6 gene are the genetic basis of two heritable disorders 
related to soft tissue calcification: pseudoxanthoma elasticum (PXE) and generalized 
arterial calcification of infancy (GACI). Pseudoxanthoma elasticum is a recessive genetic 
disorder characterized by progressive calcification of elastic fibers in the skin, in the 
medial layer of middle-sized arteries and within the Bruch’s membrane of the retina. Most 
severe clinical consequences of the disease are the risk of cardiovascular events and the 
macular degeneration leading to loss of visual acuity. While PXE is underlined by high 
phenotypic variability; i.e. milder forms of the disease often remain undiagnosed even for 
lifetime; generalized arterial calcification of infancy is a more severe disorder 
characterized by the calcification of the lamina media of large and medium sized arteries 
that is associated with the proliferation of the intimal layer, leading to stenosis of the 
vessels and myocardial ischemia within the first months of life. Since 2000, when 
mutations at the ABCC6 locus were identified as the genetic background of PXE, more 
than 400 sequence variations affecting this region were published. Despite the large 
number of ABCC6 mutations, identified thus far, no clear genotype-phenotype correlation 
has emerged.  
The ABCC6 transporter has also been extensively studied since than. Tissue distribution 
and subcellular localization experiments revealed marked liver expression with exclusive 
basolateral localization and with no or extremely low within tissues affected by the 
disease, suggesting a role for ABCC6 in the sinusoidal efflux of an unidentified metabolite. 
According to this PXE was hypothesized as a metabolic disorder. However, the 
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physiologic substrate of ABCC6 and the pathological background of the disease still 
remain unknown. 
Patients with a single gene Mendalian disorder, the PXE-like syndrome, underlined by 
mutations in the gamma-glutamyl carboxylase (GGCX) gene, also develop cutaneous signs 
similar to PXE. The GGCX enzyme is responsible for the secondary modification, thus the 
activation of Ca-chelating proteins. These include vitamin-K dependent coagulation factors 
and proteins participating in anti-calcification processes of connective tissues. This 
suggested that while the defective GGCX enzyme could be responsible for the hepatic and 
peripheral manifestation of PXE-like syndrome the lack of vitamin-K compounds at 
peripheral tissues would be the basis of ABCC6 associated calcification processes in case 
of PXE and the ABCC6 related GACI cases. According to this hypothesis ABCC6 would 
be the transporter of (a) vitamin-K form or derivative utilized in peripheral tissues. 
 
Aims 
In one part of my PhD period I focused on the functional properties of the transporter 
and investigated its potential involvement in the Vitamin K transport.  
The other part of my work aims to analyze disease-associated mutations of the ABCC6 
gene and those of the transporter.  
 
My specific aims were as follows: 
1. To synthesize and to purify the radioactively labeled and the unlabeled GSH 
conjugated form of the VitK3 metabolite (VK3GS). 
To test ABCC6 transporter and additional hepatic ABC transporters, ABCC1, 
ABCC2, ABCC3, and ABCG2, for their ability to transport the VK3GS conjugate 
in in vitro vesicular transport measurements. I aimed to determine whether ABCC6 
or any of the above hepatic ABC proteins is a transporter of the VK3GS conjugate.  
2. Since there were already hundreds of disease-causing mutations described in the 
literature affecting the ABCC6 gene thus far we decided to establish a validated 
database of the sequence variations. 
3. In order to recall structure and function data embedded amongst the numerous 
disease-associated mutations we aimed to generate three dimensional homology 
models of the ABCC6 protein. 
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4. In order to analyze the consequences of disease-associated mutations of the 
ABCC6 transporter in vitro I have selected missense mutations that are frequent in 
PXE and affect conserved functional or structural surfaces of the protein. I aimed to 
investigate their functional properties in vitro in vesicular transport measurements 
and to investigate their subcellular localization in vitro in MDCKII mammalian 
cells. As part of a collaborative work our specific aim was to identify transport 
competent but mislocalized mutants. These may serve as potential candidates in 
pharmacological rescue experiments targeting stability/folding correction of disease 
associated missense mutants both in vitro and in vivo.  
 
Methods 
Data processing of ABCC6 database 
Published sequence variants of the ABCC6 gene were collected from papers available in 
the PubMed database. The online database is powered by an LOVD platform; it was 
created in a collaborative work with PXE International and it operates on the server of the 
NCBI. 
Model building 
Protein sequence alignments of ABCC6, Sav1866, HlyB–ABC, CFTR–ABC and P-gp 
proteins were generated by ClustalW2 program using the default settings. Homology 
model building was performed by using the Sav1866 bacterial ABC transporter 
coordinates (PDB Accession No: 2ONJ 3.4Å) as well as the coordinates of the HlyB 
ABC–ABC dimer with ATP-Mg and those of the N-ABC CFTR homodimer (PDB 
Accession No: 1XEF 2.5Å, 2PZE 1.7Å, respectively) in case of the closed conformation 
(outward facing) model and the coordinates of the mouse P-gp (PDB Accession No: 3G5U 
3.8Å) in case of the open conformation model. Two hundred structures were generated 
using the Modeller 9.3 software package. The one with the lowest objective function of the 
200 generated models were used in the present study. Figures were made with PyMOL 
software. Fisher exact test was used for statistical calculations. 
DNA constructs of ABCC6 variants 
p.S1121W, p.T1301I, p.Q1347H and p.R1459C mutants were genereted by overlap 
extension mutagensis PCR method in pAcUw21L baculovirus transfer vector. These 
constructs were used to express ABCC6 mutants in Sf9 (Spodoptera frugiperda) insect 
cells. The cDNA cassettes harbouring the above PXE-associated missense mutations were 
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subcloned into SpSldS retroviral vector and pLIVE vector that were used for in vitro 
expression in MDCKII cells and for in vivo experiments in mice, respectively.  
Cell culturing 
Sf9 insect cells were maintained at 27°C in TNM-FH medium supplied with FBS, 
penicillin and streptomycin. Phoenix-Ampho and MDCKII cells were cultured in 
humidified CO2 thermostate at 37°C, in DMEM medium supplied with FBS, penicillin and 
streptomycin. 
Expression of S1121W, T1301I, Q1347H and R1459C variants in Sf9 cells 
Sf9 (Spodoptera frugiperda) insect cells were co-transfected with linearized baculovirus 
vector and pAcUw21L vector containing ABCC6 wt or the mutant cDNA constructs, as 
recommended by the manufacturer (BaculoGold kit (BD Biosciences Pharmingen). Viral-
supernatants corresponding to the highest expression levels were cloned with end point 
dilution method and 3x107 cell were transfected with the amplified virus. Cells 
overexpressing recombinant proteins were harvested after 72 hours.  
Membrane preparation and the determination of membrane protein content 
After washing and homogenization steps using Potter-Elvehjem tissue grinders 
(Wheaton) membrane fraction of the cell was isolated with differential ultracentrifugation 
at 60.000G. Membrane pellet was suspended to obtain approximately 5-10 mg/ml total 
protein concentration and subjected for final homogenization. Aliquots of membrane 
preparation samples were stored at -70°C. Total protein content of the membrane 
preparation samples was measured with the modified Lowry-method. The relative amount 
of uptake-competent inside-out vesicles in different membrane preparation samples was 
estimated on the bases of 45Ca uptake by endogenous Ca-transporters in Sf9 cells. 
Leammli SDS-polyacrylamide gel electrophoresis and immunoblot  
Membrane preparation and cell lysate samples were diluted in disaggregating buffer and 
loaded on 6-7.5% polyacrylamide gel with Protean electrophoresis equipment (Bio-Rad). 
Proteins were transferred to polyvinylidene difluoride (PVDF) membranes by standard 
electro-blotting with Mini-Trans-Blot or by semidry blot equipments according to the 
manufacturer’s protocols (Bio-Rad). ABCC6 wt and mutant proteins were detected with 
HB6 polyclonal or M6II-7 monoclonal antibodies. HRP-conjugated secondary antibodies 




Synthesis and purification of the [3H]K3GS conjugate.  
280µM [3H]GSH was rapidly added to 0.1M K3 solved in ethanol. The reaction was 
incubated on 4oC overnight in silanized glass tubes. [3H]K3GS crystals were vacuum 
dried, solved in 5% trifluoric acetate and purified by HPLC. Unlabeled VK3GS has been 
synthesized similarly and purified by chrystallization and chloroform-washing. The 
chemical identity of the compounds were verified by HPLC-MS. VK3GS solutions were 
stored at -20oC in dark glass vials and used within 30 days. 
[3H]LTC4, [3H]E2-17G, [3H]MTX and [3H]K3GS Transport measurements 
Measurements were performed with rapid filtration method. ATP-dependent transport 
was calculated from data measured in the presence and absence of 4 mM MgATP. 
Radioactivity was detected in OptiFluor scintillation cocktail (Perkin Elmer) with a 
scintillation counter (Wallac 1409 DSA). Transport kinetics were calculated and visualized 
with KaleidaGraph (Synergy) Software.  
Retroviral expression of ABCC6 mutants in MDCKII cells 
Phoenix-Ampho “packaging” cells/well were co-transfected with the recombinant 
retroviral vector pSpSldS containing the wild type or mutant constructs of ABCC6 cDNA 
parallel with helper vectors expressing M57 and GALV viral proteins. Transfection was 
performed using the calcium phosphate precipitation method, according to the 
manufacturers protocol (GIBCO). Virus containing supernatant was collected and 
MDCKII cells were transduced with the previously harvested recombinant retroviruses. 
Polybrene was also added in a final concentration of 6 mg/ml. After centrifugation (1000G, 
90min) cells were maintained at 37°C in humidified, 5% CO2 incubator.  
Immunostaining of MDCKII cells and confocal imaging 
In order to obtain nonpolarized cell culture MDCKII cells were maintained on 8-well 
chambers (coverslips) and subjected for immunostaining after two days. To obtain 
polarized cultures MDCKII cells were maintained on Transwells and subjected for 
immunostaining 8-10 days after reaching confluency.  
Before immunostaining cells were washed in Dulbecco’s Phosphate Buffered Saline, fixed 
with 4% paraformaldehide and treated with pre-cooled methanol for 5 min. After blocking, 
samples were incubated with primary and secondary antibodies solved in blocking buffer 
for 1 hour. Nuclei were stained with DAPI if it was indicated and samples were subjected 
for confocal microscopy. 
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Confocal imaging of immunostained MDCKII samples was performed using Olympus 
IX-81/FV500 laser scanning confocal microscope; images were analyzed by Olympus 
FluoView 4.7 software. 
 
Results 
1. I have synthesized and purified unlabeled and radioactively labelled VK3GS 
conjugate from VitK3 and GSH or [3H]GSH, respectively.  
2. I have investigated the ATP-dependent VK3GS transport of ABCC6, ABCC1, 
ABCC2, ABCC3 and ABCG2 transporters on validated membrane vesicles. In case 
of ABCC6 transporter I could not detect significant VK3GS-transport, indicating 
that ABCC6 is most probably not involved in the export of VK3GS from 
hepathocytes [Fülöp et al., 2011]. 
3. In similar experimental conditions ABCC1 transporter was proved to be a high 
capacity transporter of VK3GS, with approximate KM and Vmax values of 1.45µM 
and 240 pmol/mg membrane protein/min, respectively [Fülöp et al., 2011]. This 
transport was specific, as 500nM of LTC4, the physiological substrate of ABCC1, 
and the common MRP-inhibitor, MK571 (10µM) inhibited the transport to a 
residual activity of 35% and 23%, respectively. No ATP dependent transport of the 
VK3GS compound was observed in case of the ABCC1 inactive mutant G771D. 
4. These assays also revealed ABCC2 as a potential low capacity transporter of the 
VK3GS conjugate, with a characteristic “co-transport” mechanism.  
5. No transport of VK3GS by ABCC3 and ABCG2 transporters could be detected 
amongst similar conditions in our transport system. 
 
6. I have contributed to the establishment of a validated database collecting all the 
PXE and GACI related ABCC6 mutations that has been published in the literature. 
Most frequently used information, i.e.: the sequence variation at DNA level; the 
sequence variation at protein level; the status: mutation/polymorphism; the type of 
alteration; the genomic position of the alteration; the genomic region affected; the 
protein region affected; in case of a “C>T” variation if it has occurred at a 
“5’CpG”, is listed in the table. All publications that report on a particular sequence 
variation are given. In every case where it was available allele frequency data is 
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also indicated. These data served as the major basis of the online “ABCC6 LOVD” 
database (http://www.ncbi.nlm.nih.gov/lovd/home.php?select_db=ABCC6).  
7. I have also analyzed the CG content of the 4512 nucleotide long cDNA as well as 
the distribution of CpG dinucleotides within the coding region. We concluded that 
the distribution of single nucleotide substitutions within the coding sequence is not 
random, CpGs are more frequently affected. 29% of the single nucleotide 
substitutions affecting the coding region occurred on 312 bases (156 5’CpG sites) 
that correspond to the 6,9 % of the coding nucleotides. 
8. I have also shown that mutational events affecting CpG dinucleotides largely 
contribute to the number of disease causing mutations in PXE and GACI diseases. 
Mutations identified on CpG sites along the ABCC6 gene represent the 20.5 % of 
all disease causing mutations (220), based on the data reported until the end of 
2013. 
 
9. I have contributed to the generation of homology models representing the inward-
facing and the outward-facing conformations of the ABCC6 protein. These models 
were generated on the basis of the crystal coordinates of the Sav1866 (PDB ID: 
2ONJ, 3.4Å) and those of the mouse Abcb1 (PDB ID: 3G5U) transporters.  
10. We analyzed the distribution of disease-associated missense mutations on predicted 
functional and structural surfaces of the protein and detected the significant 
clustering of missense mutations on the ABC-ABC and the ABC-ICL contact 
surfaces [Fulop et al., 2009]. These findings are considered as the first genetic 
proof of the essential role of these domain-domain interactions. I have also 
investigated and excluded the potential role of DNA structure-related mutational 
hot spots in the observed clustering.  
11. In contrast to the results of Kelly et al., 2010 I questioned the predictive value of 
homology models, e.g. if homology models are useful in forecasting pathological 
consequences of individual amino acid replacements in the protein structure.  
 
12. I have investigated the structure and function consequences of mutations affecting 
the protein structure by expressing and analyzing four disease-associated missense 
mutants: S1121W, T1301I, Q1347H and R1459C, of the ABCC6 protein in vitro. I 
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have identified them as transport active but mis-localized variants [Pomozi, 
Brampton, Fülöp, Chen, Apana, Li, Uitto, LeSaux and Váradi, 2014]. 
 
Discussion 
ABCC6 is thought to transport (an) unidentified substrate(s) that directly or indirectly 
prevents ectopic soft tissue calcification in organs affected by PXE and GACI diseases. 
Based on in vitro transport experiments I disproved a recent hypothesis suggesting a 
Vitamin K metabolite, the VK3GS conjugate, as potential physiological substrate of the 
ABCC6 transporter. In vitro and in vivo data of others also supported my results, thus I 
concluded that ABCC6 protein is not involved in the elimination of VK3GS conjugate 
from hepathocytes. 
Since 2000, when mutations at the ABCC6 locus were identified as the genetic 
background of PXE, more than 400 sequence variations affecting this region were 
published. As it is impossible to characterize all the protein variants using regular in vitro 
or in vivo methods, the development of appropriate in silico approaches focusing on 
structural and functional consequences of sequence variations have great importance. 
Validated databases, collecting published experimental evidences related to mutations as 
well as clinical phenotype data of affected patients are also extremely helpful.  
The collection of ABCC6 variants, generated in Budapest by Orsolya Symmons and 
me, served as the major basis in establishing the online database  
( http://www.ncbi.nlm.nih.gov/lovd/home.php?select_db=ABCC6).  
I have also contributed to the generation of homology models of ABCC6 protein. The 
homology model of ABCC6 [Fulop et al, 2009], also linked to the online database, gives 
an opportunity to answer structural and/or functional consequences of mutations via 
embedding missense mutations in a structural view of the protein. Our observation that 
disease associated ABCC6 mutations show significant clustering on the ABC-ABC and 
ABC-ICL contact surfaces in the predicted structure was the first genetic proof supporting 
the fundamental role of the ABC-ICL intramolecular surfaces.  
In vitro cell free activity assays as well as in vitro and in vivo cellular models expressing 
recombinant proteins are basic experimental systems that may lead to the better 
understanding of the molecular mechanisms of a protein. As part of a large collaborative 
work I characterized the transport function and the subcellular targeting of four disease-
	  
 9	  
associated missense mutants, S1121W, T1301I, Q1347H and R1459C, of the ABCC6 
protein in vitro. I have identified them as transport active but mis-localized variants.  
These mutants served as proper candidates for in vitro and in vivo folding correction 
experiments. Results of these experiments may serve as the first steps toward allele 
specific therapy in PXE and GACI diseases in which no efficient therapy exists.  
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